

EMA/164271/2017

European Medicines Agency decision

P/0107/2017

of 11 April 2017

on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (LENVIMA, Kispplx), (EMA-001119-PIP02-12-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0107/2017

of 11 April 2017

on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (LENVIMA, Kisplyx), (EMA-001119-PIP02-12-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0125/2013 issued on 28 May 2013, the decision P/0040/2014 issued on 5 March 2014 and the decision P/0282/2014 issued on 28 October 2014.

Having regard to the application submitted by Eisai Europe Ltd on 12 December 2016 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 February 2017, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for lenvatinib (LENVIMA, Kisplyx), capsule, hard, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Eisai Europe Ltd, European Knowledge Centre, Mosquito Way, AL10 9SN - Hatfield, Herts, United Kingdom.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/857530/2016
London, 24 February 2017

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001119-PIP02-12-M03

Scope of the application

Active substance(s):

Lenvatinib

Invented name:

LENVIMA

Kisplyx

Condition(s):

Treatment of papillary thyroid cancer

Treatment of follicular thyroid cancer

Treatment of osteosarcoma

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Capsule, hard

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Eisai Europe Ltd

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Eisai Europe Ltd submitted to the European Medicines Agency on 12 December 2016 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0125/2013 issued on 28 May 2013, the decision P/0040/2014 issued on 5 March 2014 and the decision P/0282/2014 issued on 28 October 2014.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 3 January 2017.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Conditions

Treatment of follicular thyroid carcinoma, treatment of papillary thyroid carcinoma and treatment of osteosarcoma

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- for capsule, hard, oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan

2.1. Condition

Treatment of follicular thyroid carcinoma and treatment of papillary thyroid carcinoma

2.1.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with ¹³¹I-refractory follicular or papillary thyroid cancer

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an oral suspension prepared from the hard capsule
Non-clinical studies	2	Study 2 Toxicity study in juvenile rats Study 3 Toxicity study in juvenile rats

Clinical studies	1	Study 5 Open-label, multi-centre, non-controlled trial to evaluate pharmacokinetics, pharmacodynamics, tolerability and safety of lenvatinib in children from 2 years to less than 18 years of age with a relapsed or refractory solid malignant tumour and, in patients with osteosarcoma, an extension phase to evaluate lenvatinib in combination with ifosfamide and etoposide
------------------	---	--

2.2. Condition

Treatment of osteosarcoma

2.2.1. Indication(s) targeted by the PIP

Treatment of paediatric patients with a first relapse of osteosarcoma

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.2.3. Pharmaceutical form(s)

Capsule, hard

2.2.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 As for conditions treatment of follicular thyroid carcinoma and treatment of papillary thyroid carcinoma
Non-clinical studies	3	Study 2 As for conditions treatment of follicular thyroid carcinoma and treatment of papillary thyroid carcinoma Study 3 As for conditions treatment of follicular thyroid carcinoma and treatment of papillary thyroid carcinoma Study 4 Pharmacology study of lenvatinib in combination with ifosfamide and etoposide in paediatric tumour models
Clinical studies	2	Study 5 As for conditions treatment of follicular thyroid carcinoma and treatment of papillary thyroid carcinoma

		Study 6 Multi-centre, randomized, controlled trial to evaluate the efficacy and safety of lenvatinib as add-on to ifosfamide and etoposide in children from 5 years to less than 18 years (and adults) with relapsed osteosarcoma
--	--	---

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2022
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of papillary thyroid cancer
2. Treatment of follicular thyroid cancer
3. Treatment of osteosarcoma

Authorised indication(s):

- LENVIMA is indicated for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
- Kisplyx is indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.

Authorised pharmaceutical form(s):

Hard capsule

Authorised route(s) of administration:

Oral use